IC-MPGN Market Emerging as a High-Growth Healthcare Investment Space Through 2036 - DelveInsight

DelveInsight's "Immune Complex Membranoproliferative Glomerulonephritis Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Immune Complex Membranoproliferative Glomerulonephritis, historical and forecasted epidemiology as well as the Immune Complex Membranoproliferative Glomerulonephritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Immune Complex Membranoproliferative Glomerulonephritis, offering comprehensive insights into the Immune Complex Membranoproliferative Glomerulonephritis revenue trends, prevalence, and treatment landscape. The report delves into key Immune Complex Membranoproliferative Glomerulonephritis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Immune Complex Membranoproliferative Glomerulonephritis therapies. Additionally, we cover the landscape of Immune Complex Membranoproliferative Glomerulonephritis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Immune Complex Membranoproliferative Glomerulonephritis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Immune Complex Membranoproliferative Glomerulonephritis space.

To Know in detail about the Immune Complex Membranoproliferative Glomerulonephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Immune Complex Membranoproliferative Glomerulonephritis Market Forecast
https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Immune Complex Membranoproliferative Glomerulonephritis Market Report:
• The Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) market size was valued at approximately USD 30 million in 2025 across the 7MM and is projected to witness substantial expansion during the 2026-2036 forecast period, driven by a robust compound annual growth rate (CAGR) of 26%.
• In March 2026, Biogen and Apellis Pharmaceuticals announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire Apellis.
• In February 2026, SanegeneBio announced that SGB-9768 has received Orphan Drug Designation from the US FD for the treatment of IC-MPGN.
• In December 2025, Updated 52-week results from the Phase III VALIANT trial and the VALE extension study showed that pegcetacoplan continued to provide sustained reductions in proteinuria while helping preserve kidney function in patients with Complement 3 Glomerulopathy (C3G) and primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN). These findings further support the therapy's long-term efficacy and favorable safety profile.
• In July 2025, Apellis Pharmaceuticals announced that US FDA has approved EMPAVELI (pegcetacoplan) as the first treatment for primary IC-MPGN in patients 12 years of age and older, to reduce proteinuria. The approval of EMPAVELI is based on positive six-month results from Phase III (VALIANT) study.
• In July 2025, The U.S. FDA approved Empaveli (pegcetacoplan), developed by Apellis Pharmaceuticals and Sobi, for the treatment of patients aged 12 years and older with Complement 3 Glomerulopathy (C3G) and primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) to reduce proteinuria. The approval was based on positive findings from the Phase III VALIANT trial, which demonstrated meaningful reductions in proteinuria along with stabilization of kidney function. This milestone established pegcetacoplan as the first FDA-approved therapy specifically indicated for primary IC-MPGN.
• In March 2025, Novartis' Fabhalta (iptacopan) received U.S. FDA approval as the first therapy indicated for adults with Complement 3 Glomerulopathy (C3G) to reduce proteinuria. While the approval is specific to C3G, it represents a significant advancement in the treatment of complement-mediated kidney diseases and may help pave the way for future therapies targeting primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) due to the shared underlying complement-driven disease mechanisms between the two conditions.
• According to DelveInsight's estimates, in 2025, the total number of diagnosed prevalent cases of IC-MPGN in the 7MM were about 7,000.
• In 2025, the US accounted for the highest number of diagnosed prevalent cases of IC-MPGN, with ~3,500 cases, followed by Japan.
• According to DelveInsight's estimates, males represent more than 50% of the total IC-MPGN cases in the US in 2025.
• The cases of IC-MPGN are more prevalent in adults than in pediatrics.
• Although the incidence of idiopathic IC-MPGN remains unknown, the estimated global annual incidence of C3G ranges from 1 to 3 cases per million individuals. The risk of progression to kidney failure is substantial, with up to 30-35% of patients with C3G or idiopathic IC-MPGN developing kidney failure within 10 years of diagnosis.
• Key Immune Complex Membranoproliferative Glomerulonephritis Companies: SanegeneBio, Novartis, Apellis Pharmaceuticals, and others.
• Key Immune Complex Membranoproliferative Glomerulonephritis Therapies: SGB-9768, Iptacopan (LNP023), Pegcetacoplan (APL-2), and others
• The Immune Complex Membranoproliferative Glomerulonephritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Immune Complex Membranoproliferative Glomerulonephritis pipeline products will significantly revolutionize the Immune Complex Membranoproliferative Glomerulonephritis market dynamics.
• In 2023, the total diagnosed prevalent population of IC-MPGN across the 7MM was estimated to be around 7,000.
• In 2023, the diagnosed prevalent population of IC-MPGN in the United States was estimated to be around 3,770.
• In 2023, Germany had the highest diagnosed prevalent population of IC-MPGN in the EU4 and the UK, followed by Spain, with Italy reporting the fewest cases.

Immune Complex Membranoproliferative Glomerulonephritis Overview
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a type of kidney disorder characterized by inflammation and changes in the kidney's glomeruli, the tiny filtering units. It occurs when immune complexes, which are formed by antibodies and antigens, accumulate in the kidneys and trigger an immune response, leading to damage. This condition can result in symptoms such as proteinuria (excessive protein in the urine), hematuria (blood in the urine), swelling, and impaired kidney function. IC-MPGN can be caused by infections, autoimmune diseases, or certain cancers, and treatment typically focuses on addressing the underlying cause and managing symptoms to prevent kidney damage.

Get a Free sample for the Immune Complex Membranoproliferative Glomerulonephritis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 202 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation:
The Immune Complex Membranoproliferative Glomerulonephritis market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalence of Immune Complex Membranoproliferative Glomerulonephritis
• Prevalent Cases of Immune Complex Membranoproliferative Glomerulonephritis by severity
• Gender-specific Prevalence of Immune Complex Membranoproliferative Glomerulonephritis
• Diagnosed Cases of Episodic and Chronic Immune Complex Membranoproliferative Glomerulonephritis

Download the report to understand which factors are driving Immune Complex Membranoproliferative Glomerulonephritis epidemiology trends @ Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Forecast
https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Immune Complex Membranoproliferative Glomerulonephritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Immune Complex Membranoproliferative Glomerulonephritis market or expected to get launched during the study period. The analysis covers Immune Complex Membranoproliferative Glomerulonephritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Immune Complex Membranoproliferative Glomerulonephritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Immune Complex Membranoproliferative Glomerulonephritis Therapies and Key Companies
• Iptacopan (LNP023): Novartis Pharmaceuticals
• Pegcetacoplan (APL-2): Apellis Pharmaceuticals
• SGB-9768: SanegeneBio

Discover more about therapies set to grab major Immune Complex Membranoproliferative Glomerulonephritis market share @ Immune Complex Membranoproliferative Glomerulonephritis Treatment Landscape
https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Immune Complex Membranoproliferative Glomerulonephritis Market Drivers
• Rising awareness and improved diagnosis of rare glomerular diseases through advances in renal pathology and complement testing.
• Increasing prevalence of chronic kidney disease (CKD) and immune-mediated renal disorders, driving demand for effective therapies.
• Growing research into complement pathway inhibitors, targeted immunotherapies, and precision medicine approaches for IC-MPGN.
• Expansion of orphan drug incentives and regulatory support encouraging the development of therapies for rare kidney diseases.
• Increasing investment by biotechnology and pharmaceutical companies in nephrology-focused clinical research.

Immune Complex Membranoproliferative Glomerulonephritis Market Barriers
• Rare disease prevalence, resulting in a limited patient population and constrained commercial opportunities.
• Lack of FDA-approved therapies specifically indicated for IC-MPGN, with current treatment relying largely on off-label immunosuppressive agents.
• Challenges in timely and accurate diagnosis due to overlapping clinical and pathological features with other glomerular diseases.
• Limited understanding of disease pathogenesis and heterogeneity, complicating drug development and treatment selection.
• High costs associated with developing therapies for orphan indications and conducting adequately powered clinical trials.

Scope of the Immune Complex Membranoproliferative Glomerulonephritis Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Immune Complex Membranoproliferative Glomerulonephritis Companies: SanegeneBio, Novartis, Apellis Pharmaceuticals, and others
• Key Immune Complex Membranoproliferative Glomerulonephritis Therapies: SGB-9768, Iptacopan (LNP023), Pegcetacoplan (APL-2), and others
• Immune Complex Membranoproliferative Glomerulonephritis Therapeutic Assessment: Immune Complex Membranoproliferative Glomerulonephritis current marketed and Immune Complex Membranoproliferative Glomerulonephritis emerging therapies
• Immune Complex Membranoproliferative Glomerulonephritis Market Dynamics: Immune Complex Membranoproliferative Glomerulonephritis market drivers and Immune Complex Membranoproliferative Glomerulonephritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs, KOL's views, Analyst's views, Immune Complex Membranoproliferative Glomerulonephritis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.